Imipenem/Cilastatin Aptapharma

Imipenem, the active ingredient in Imipenem/Cilastatin Aptapharma, is a carbapenem antibiotic presented as an intravenous formulation for use in hospitalized patients. It is combined with cilastatin to treat a range of serious bacterial infections, including complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired bacterial pneumonia, skin and soft‑tissue infections, and severe sepsis or septic shock.

GNH USA supplies Imipenem/Cilastatin Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/cilastatin is a carbapenem antibiotic used to treat severe bacterial infections across several organ systems. - Complicated intra‑abdominal infections: provides broad‑spectrum coverage to eradicate Gram‑negative, Gram‑positive and anaerobic pathogens. - Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis and cystitis. - Hospital‑acquired bacterial pneumonia: targets multidrug‑resistant organisms responsible for ventilator‑associated pneumonia. - Skin and soft‑tissue infections: treats deep or necrotizing infections where other agents may fail. - Severe sepsis and septic shock: offers rapid bactericidal activity in critically ill patients.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruptions. - Injection site reactions: pain, erythema, or swelling at the infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with pre‑existing CNS disorders or high plasma concentrations. - Clostridioides difficile‑associated colitis: severe diarrhea with possible pseudomembranous colitis. - Anaphylaxis: rapid onset of airway compromise, hypotension, and urticaria. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: extensive skin detachment and mucosal involvement. - Renal toxicity: elevated serum creatinine or reduced urine output.

Before initiating therapy, clinicians should consider several safety measures. - Renal function assessment: adjust dosing in patients with impaired clearance. - Seizure risk evaluation: avoid in individuals with a history of epilepsy or CNS disease. - Hypersensitivity screening: discontinue if signs of allergic reaction appear. - Concomitant CNS depressants: use with caution as they may lower seizure threshold. - Dose adjustment in renal impairment: follow established guidelines for reduced creatinine clearance. - Store at below 25°C: keep in the original pack, protect from moisture and light.

Imipenem/cilastatin may interact with other medicines, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Valproic acid: reduces valproate levels, risking seizure breakthrough. - Probenecid: decreases renal clearance, increasing imipenem toxicity. - Ganciclovir: carbapenems may diminish antiviral efficacy. Moderate Interactions (Monitor Closely): - Loop diuretics: heightened risk of nephrotoxicity. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate renal impairment. - Warfarin: possible alteration of INR, requiring closer monitoring.